Baumer S.A (BALM3) Fair Value & Analysis
Healthcare · BR · Market cap R$254M
Fair value as of: Aug 20, 2026
From 26 valuation models · updated today
A solid business, screening 56% undervalued on our models.
What matters now
- The rarer combination: high quality (71/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (R$30.48). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
60‑month range R$3.70 – R$30.00 · fair‑value band R$30.48 – R$50.81 · the R$26.00 price screens below the R$40.65 fair value. Dashed = 300-day average. As of Aug 20, 2026.
Analysis
Baumer S.A (BALM3) currently trades at R$26.00, while our model-based Fair Value estimate is R$40.65, implying the stock looks roughly 56.4% undervalued today. The Quality Score stands at 71/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Baumer S.A generated revenue of R$212M at a net margin of 9.1%. Revenue declined 2.8% year over year. It earns a return on equity of 13.5%. Net debt stands at R$5.4M. Fundamentals as of Aug 20, 2026
Our scenario range runs from R$30.48 (bear case) to R$50.81 (bull case); at R$26.00, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 53% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at 56%, BALM3 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Dividend Discount (R$69.04) versus Asset-Based (R$10.48). Highest evidence: Growth DCF (80).
Notify me when BALM3 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Baumer S.A., together with its subsidiaries, engages in the development, industrialization, trade, production, import, export, and technical assistance in products for hospitals and industries related to the health area in Brazil and internationally.
Full company description
Baumer S.A., together with its subsidiaries, engages in the development, industrialization, trade, production, import, export, and technical assistance in products for hospitals and industries related to the health area in Brazil and internationally. The company offers orthopedic devices, such as conventional prosthesis, spine and neurosurgery, non-conventional prosthesis, trauma, and biomaterials; and hospital equipment, including CSSD, surgical center and ICU, and sterilization process monitoring. It also provides life science equipment comprising pharmaceutical production and research laboratory; bone regeneration consisting of structural, raw material, and specialties; and maintenance, sterilization process monitoring, rental, CME equipment management, technological update, and replacement parts, as well as inspection, qualification, and calibration services. In addition, the company offers the Baumer Academy platform for specialized courses in the areas of hospital equipment, bone regeneration, and orthopedic devices. Baumer S.A. was incorporated in 1952 and is headquartered in Pacaembu, Brazil.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Baumer S.A reported revenue of R$214M in FY2025 versus R$268M in FY2021, a compound −5.5%/yr. Reported net income was R$18.1M in FY2025, compounding +15.6%/yr from FY2021.
of which total revenue +6.0 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch BALM3: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 204 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $182.09 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Coloplast A/S COLOB | kr 429.70 | kr 382.22 | -11% |
| Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 | ¥77.48 | ¥27.22 | -65% |
Compare Baumer S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Baumer S.A (BALM3) overvalued or undervalued?
What is the fair value of BALM3?
What is the quality score of BALM3?
What is the revenue of Baumer S.A (BALM3)?
What is the net profit margin of BALM3?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Baumer S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.